Aller au contenu

Michael Marks

@drmichaelmarks.bsky.social did:plc:tcnl3lteuyjseti66zxsbuda

NIHR Research Professor Professor of Medicine at LSHTM. Lead for Integrated Academic Training at LSHTM. Consultant in Infectious Diseases at UCLH. Syphilis & STIs, Neglected Tropical Diseases, Emerging Infectious Diseases, Group A Strep, Pragmatic Trials

Sur Bluesky depuis le

Abonnés
6 225
Abonnements
485
Posts
653
Jours dans les classements
0

Résumé

Michael Marks (@drmichaelmarks.bsky.social) est sur Bluesky depuis le 10 octobre 2024. Le compte a 6 225 abonnés, suit 485 comptes et a publié 653 posts.

Présence dans les classements

Les meilleurs jours où les posts de ce compte sont entrés dans le top quotidien de Debya.

Ce compte n’est encore apparu dans aucun classement quotidien.

Posts aimés récemment

J’aime publics du réseau Bluesky.

  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    I’ll be hiring technicians, bioinformaticists, data scientists, and postdocs for a very multidisciplinary team. Graduating soon or looking for a job next summer? Please reach out directly if you’re interested in working with me in Nashville!

    Voir le post
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    I would be remiss not to share that my brilliant husband Josh (not on Bluesky) will also be joining VUMC as the Medical Director of New Technology and Strategy for Vanderbilt Medical labs, and ID diagnostics service chief. He will be looking for a Leishmania genomics-focused postdoc.

    Voir le post
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    Ok, part two of my exciting news: I’ll be starting my lab as an Assistant Professor of Pediatrics at Vanderbilt next July, focusing on functional genomics of congenital syphilis.

    Voir le post
  • Steven Tong@steventong.bsky.social

    How about ESBLs where pip/taz is better than ceftriaxone? I became more supportive of pip/taz when I realised that for patients with likely GNB sepsis pip/taz had probably 95%+ activity compared to around 85% with ceftriaxone. And that's not because of Pseudomonas.

    Voir le post
  • Nicole Lieberman, PhD@nicolelieberman.bsky.social

    Absolutely thrilled to share that my NIAID Director’s New Innovator Award (DP2) has been funded. I’ll be using functional genomics, biochemistry, and immunological techniques to understand the mechanisms and drivers of immune evasion by Treponema pallidum, the bacterium that causes syphilis.

    Voir le post

Connectez-vous pour en voir plus

Comptes bloqués

Sur Bluesky, les blocages sont publics.